Physician profile
Igor Romanov
NPI 1457565269
$11,899.62
in general payments reported to CMS, 2019-2025
26 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 89% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,029 · 2022: $2,955 · 2023: $3,290 · 2024: $2,262 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,721 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,721.44 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $1,662.92 | 2022-2024 | Vtama |
| Incyte Corporation | $1,329.47 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $1,285.43 | 2021-2025 | |
| Janssen Biotech, INC. | $1,254.31 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $883.62 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $862.76 | 2021-2025 | Ilumya |
| Leo Pharma INC. | $786.69 | 2021-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $621.83 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $548.08 | 2021-2024 | |
| Lilly USA, LLC | $500.51 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $393.58 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $392.61 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $313.94 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $210.82 | 2022-2024 | Sotyktu |
| Medimetriks Pharmaceuticals, INC. | $162.67 | 2023 | Neo-Synalar |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $138.49 | 2021-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $111.75 | 2021 | |
| Galderma Laboratories, L.P. | $111.65 | 2024 | Aklief |
| Organon LLC | $90.77 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $86.20 | 2021-2024 | |
| Strata Skin Sciences, INC. | $45.63 | 2024-2025 | Xtrac |
| Mallinckrodt Hospital Products INC. | $31.31 | 2025 | Acthar |
| Botanix Sb INC | $30.19 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.59 | 2024 | Siliq |
| Epi Health, LLC | $11.86 | 2022 | |
| Biofrontera INC. | $9.94 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Romanov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.